2025
Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations that Overcome it's Feedback Inhibition of RAC1 and Migration.
Gadal S, Boyer J, Roy S, Outmezguine N, Sharma M, Li H, Fan N, Chan E, Romin Y, Barlas A, Chang Q, Pancholi P, Timaul N, Overholtzer M, Yaeger R, Manova-Todorova K, de Stanchina E, Bosenberg M, Rosen N. Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations that Overcome it's Feedback Inhibition of RAC1 and Migration. Cancer Research 2025 PMID: 39992718, DOI: 10.1158/0008-5472.can-24-2220.Peer-Reviewed Original ResearchInhibition of Rac1Rac1 activationLevels of ERK activationSecondary mutationsBRAFV600E mutationInhibition of Rac1 activityMutant Rac1Cell motilityRac1ERK activationMesenchymal migrationFeedback inhibitionRestored migrationMutationsGenetically engineered mouse modelsCell proliferationSelection of lesionsTumor evolutionPTEN inactivationTumorigenesisOncogenic driversBRAFV600EMalignant transformationBenign neviMouse model
2001
Telomere dysfunction and evolution of intestinal carcinoma in mice and humans
Rudolph K, Millard M, Bosenberg M, DePinho R. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nature Genetics 2001, 28: 155-159. PMID: 11381263, DOI: 10.1038/88871.Peer-Reviewed Original ResearchConceptsHuman intestinal neoplasiaProgression of mouseTelomerase activationHuman colorectal carcinogenesisTelomere dysfunctionInitiated lesionsIntestinal carcinomaColorectal carcinogenesisIntestinal neoplasiaHuman colorectalDysfunctionAdvanced stageMalignant transformationTumor progressionChromosomal instabilityColon carcinomaCarcinoma transitionMacroscopic adenomasTransient telomere dysfunctionEarly carcinogenesisCancer initiationHuman cancersTelomerase activityCarcinomaDifferential effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply